Brief: Neurosense Therapeutics Says Paradigm ALS Clinical Trial Demonstrates Up To 73% Improved Complication-Free Survival
09/07/2024 14:33
July 9 (Reuters) - Neurosense Therapeutics Ltd NRSN.O :
* NEUROSENSE THERAPEUTICS LTD - PARADIGM ALS CLINICAL TRIAL
DEMONSTRATES UP TO 73% IMPROVED COMPLICATION-FREE SURVIVAL
* NEUROSENSE THERAPEUTICS LTD - INTENDS TO SUBMIT RESULTS TO
REGULATORY AGENCIES, INCLUDING FDA, TO DISCUSS PRIMEC'S PATH
FORWARD IN SHORT TERM
Source text for Eikon: ID:nPn9N1VZLa
Further company coverage: NRSN.O
((Reuters.Briefs@thomsonreuters.com;))